US Patent 11,179,367: Scope, Claims, Expiration and Patent Landscape for Trikafta-Related CFTR Combinations
US Patent 11,179,367 protects pharmaceutical compositions containing elexacaftor, tezacaftor and ivacaftor, including single-tablet formulations in which tezacaftor and ivacaftor are supplied as polymer-based solid dispersions. The patent also covers specified crystalline elexacaftor material, methods for treating cystic fibrosis and tablet-manufacturing processes.
The claims are directed primarily to formulation architecture rather than to the basic chemical identity of the three CFTR modulators. The commercial relevance is strongest for Trikafta, known outside the United States as Kaftrio, although infringement depends on the precise product composition, dosage, solid-dispersion characteristics and manufacturing process.
What drug compounds are Compound I, Compound II and Compound III?
The claim structure and dosage ranges identify the compounds as follows:
| Claim designation |
Likely active ingredient |
Commercial role in Trikafta/Kaftrio |
Typical adult dose |
| Compound I |
Elexacaftor |
CFTR corrector |
100 mg |
| Compound II |
Tezacaftor |
CFTR corrector |
50 mg |
| Compound III |
Ivacaftor |
CFTR potentiator |
75 mg morning and 75 mg evening |
| Compound III-d |
A form or derivative of ivacaftor |
CFTR potentiator-related material |
Not independently established from the claim text |
The identification follows directly from the claimed dose architecture. Claim 4 recites approximately 80% active compound in each dispersion. A 60 mg to 65 mg dispersion therefore contains approximately 48 mg to 52 mg of Compound II, consistent with a 50 mg tezacaftor dose. A 90 mg to 95 mg dispersion contains approximately 72 mg to 76 mg of Compound III, consistent with a 75 mg ivacaftor dose. The 180 mg to 190 mg alternative corresponds to approximately 150 mg of ivacaftor for twice-daily dosing.
FDA describes Trikafta as a combination of elexacaftor, tezacaftor and ivacaftor for patients with cystic fibrosis who have at least one F508del mutation or another mutation responsive to the regimen [2].
What does US Patent 11,179,367 cover?
The patent has four principal protection groups:
- Broad three-component pharmaceutical compositions.
- Weight-based compositions containing two solid dispersions.
- Specific single-tablet formulations.
- Therapeutic and manufacturing methods.
The claims use open-ended “comprising” language. A product can therefore contain additional excipients, coatings or formulation components and still fall within the claims if it satisfies all required limitations.
Claim 1: broad composition claim
Claim 1 requires:
- 15 mg to 250 mg of Compound I;
- a first solid dispersion containing 10 mg to 150 mg of Compound II;
- 10 wt% to 30 wt% polymer in the first dispersion;
- a second solid dispersion containing 25 mg to 200 mg of Compound III; and
- 10 wt% to 30 wt% polymer in the second dispersion.
The claim does not require a single tablet. It can cover capsules, multiparticulate dosage forms, sachets or other oral pharmaceutical compositions if the claimed amounts and dispersion structure are present.
The claim also does not specify a particular polymer. A formulation using hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate or another suitable polymer may satisfy claim 1 if the polymer concentration falls within the claimed range.
Claim 2: dose-range alternatives
Claim 2 narrows claim 1 through five alternative dose combinations. These alternatives cover several possible ratios of the three CFTR modulators.
The alternatives are not interchangeable. A product must fit at least one complete subparagraph. A formulation that falls outside one subparagraph may still infringe another, but it cannot rely on overlapping individual ranges alone. The relevant question is whether all three active-ingredient ranges in one alternative are met.
Claim 3: composition-by-weight claim
Claim 3 shifts from milligram amounts to percentages of the total composition. It requires:
- 10 wt% to 30 wt% Compound I;
- 8 wt% to 30 wt% of the first solid dispersion;
- 70 wt% to 90 wt% Compound II within that dispersion;
- 10 wt% to 45 wt% of the second solid dispersion;
- 70 wt% to 90 wt% Compound III within that dispersion; and
- 10 wt% to 30 wt% polymer in each dispersion.
This claim can reach products that do not use the exact commercial dose but preserve the claimed composition ratios. It may also create infringement risk for line extensions and pediatric or reduced-dose products.
Claims 4 and 5: commercial single-tablet formulations
Claims 4 and 5 are the most commercially specific claims.
Claim 4 requires a single tablet containing:
- 25 mg to 125 mg of Compound I;
- 60 mg to 65 mg of a first dispersion containing 80 wt% Compound II and 20 wt% hydroxypropyl methylcellulose;
- 90 mg to 95 mg, or 180 mg to 190 mg, of a second dispersion containing:
- 80 wt% Compound III;
- 0.5 wt% sodium lauryl sulfate; and
- 19.5 wt% hydroxypropyl methylcellulose acetate succinate;
- 85 mg to 275 mg microcrystalline cellulose;
- 10 mg to 35 mg croscarmellose sodium; and
- 2 mg to 7 mg magnesium stearate.
Claim 5 covers another single-tablet dose configuration, with:
- 10 mg to 110 mg Compound I;
- 25 mg to 70 mg of the first dispersion;
- 85 mg to 195 mg of the second dispersion;
- 10 mg to 45 mg croscarmellose sodium;
- 95 mg to 280 mg microcrystalline cellulose; and
- 2 mg to 7 mg magnesium stearate.
The requirement for a single tablet materially narrows these claims. A two-tablet regimen, separate capsules or a formulation in which the two dispersions are not co-compressed may avoid claims 4 and 5 while remaining exposed to broader claims 1 or 3.
What formulations are protected by US 11,179,367?
The patent protects a formulation in which the three CFTR modulators are not simply blended as raw active pharmaceutical ingredients.
Tezacaftor and ivacaftor must be present in separate solid dispersions. Each dispersion contains the relevant drug and a polymer. The commercial formulation described by claim 4 uses:
| Component |
Claimed composition |
| Tezacaftor in first dispersion |
80 wt% |
| Hydroxypropyl methylcellulose in first dispersion |
20 wt% |
| Ivacaftor in second dispersion |
80 wt% |
| Sodium lauryl sulfate in second dispersion |
0.5 wt% |
| Hydroxypropyl methylcellulose acetate succinate in second dispersion |
19.5 wt% |
The claim language creates several technical infringement questions:
- Whether the accused material is a “solid dispersion” rather than a physical mixture.
- Whether the polymer is calculated against the total weight of the dispersion.
- Whether sodium lauryl sulfate is part of the second dispersion or is added later as an external excipient.
- Whether the active ingredient is present at the claimed wt% level after manufacturing.
- Whether the formulation has the required crystalline form of Compound I.
A generic manufacturer could attempt to avoid these claims by using a different solid-dispersion polymer, a different active-to-polymer ratio, a non-dispersed active, separate dosage units or a different tablet-excipient profile. Such changes would not automatically avoid claim 1 or claim 3.
What crystalline-form protection does the patent provide?
Claims 7 through 9 protect Compound I in Crystalline Form A.
Claim 7 requires Compound I to be Crystalline Form A. Claim 8 requires the form to be in substantially pure form. Claim 9 identifies the form by an X-ray powder diffraction pattern containing at least three specified signals selected from:
- 6.6 ± 0.2° 2θ;
- 7.6 ± 0.2° 2θ;
- 9.6 ± 0.2° 2θ;
- 12.4 ± 0.2° 2θ;
- 13.1 ± 0.2° 2θ;
- 15.2 ± 0.2° 2θ;
- 16.4 ± 0.2° 2θ;
- 18.2 ± 0.2° 2θ; and
- 18.6 ± 0.2° 2θ.
This creates a solid-state infringement issue. A competing product may contain the same chemical compound but avoid claims 7 through 9 if it uses a different polymorph, amorphous material or a mixture that does not meet the claimed diffraction limitation. It may still infringe claims 1 through 6 if the overall dosage-form limitations are met.
What methods of treatment are covered?
Claims 10 and 11 cover oral administration of the composition to treat cystic fibrosis.
Claim 11 expressly identifies patients with:
- F508del/minimal-function genotypes;
- F508del/F508del genotypes;
- F508del/gating genotypes; and
- F508del/residual-function genotypes.
The method claims link the formulation to the treatment population rather than claiming all CFTR-modulator treatment. They may be relevant to induced-infringement analysis where a product label recommends use in the claimed genotypes.
The FDA-approved Trikafta indication is broader in operational terms than the genotype list in claim 11 because FDA labeling has evolved with responsive mutations and age expansions. A label that includes patients outside the listed genotype groups would not by itself eliminate exposure for the listed populations.
What manufacturing methods are protected?
Claims 12 and 13 cover preparation of the single tablet in claim 4.
Claim 12 requires:
- Mixing Compound I with the first and second solid dispersions to form a first mixture.
- Compressing a tablet mixture containing that first mixture.
Claim 13 adds a separate excipient-mixing step:
- Mixing Compound I with the two solid dispersions.
- Mixing the first mixture with microcrystalline cellulose, croscarmellose sodium and magnesium stearate.
- Compressing the tablet mixture.
These are process claims. They do not necessarily cover every process that produces an otherwise infringing tablet. A manufacturer using wet granulation, roller compaction, ordered blending or a different sequence may avoid claims 12 and 13 while remaining exposed to product claims 4 or 5.
When does US Patent 11,179,367 lose exclusivity?
US Patent 11,179,367 issued on November 23, 2021. Its nominal patent term runs into approximately April 2039 based on the relevant application priority and filing history, subject to the patent’s certified term adjustment and any applicable patent-term extension.
The practical exclusivity date must be determined from the issued patent’s front page and USPTO Patent Center records. A patent-term extension under 35 U.S.C. § 156 would require a qualifying regulatory history and would be distinct from patent-term adjustment under 35 U.S.C. § 154(b). The patent’s expiration date should not be inferred solely from the issue date or the provisional priority date.
The FDA regulatory exclusivity period for Trikafta is separate from this patent term. FDA approval exclusivity may restrict certain ANDA or 505(b)(2) activity before the relevant exclusivity expires, but it does not extend the patent term [2, 3].
What is the Orange Book status of US 11,179,367?
The patent is associated with the Trikafta product and is relevant to FDA Orange Book patent-listing analysis. Orange Book treatment depends on the specific approved NDA, dosage form and use code. A listed patent can create a statutory certification issue for an ANDA applicant, including a Paragraph IV certification if the applicant asserts that the patent is invalid, unenforceable or not infringed [3].
The key Orange Book questions are:
- Whether US 11,179,367 is listed against the relevant Trikafta NDA.
- Which strength and dosage form are covered.
- Whether FDA lists a formulation, method-of-use or other use code.
- Whether the patent listing remains active.
- Whether the NDA holder has submitted an updated expiration date.
Because claims 1 through 5 are formulation claims and claims 10 and 11 are method claims, the patent can present both product-composition and method-of-use issues in an ANDA certification analysis.
Which companies are challenging the patent?
No challenger, Paragraph IV filing, district-court case or settlement agreement can be established from the claim text alone. The public record must be checked against:
- FDA Paragraph IV notice information;
- ANDA litigation filings under Hatch-Waxman;
- PACER and district-court dockets;
- USPTO Patent Center;
- Orange Book patent-listing records; and
- SEC disclosures from Vertex Pharmaceuticals and potential generic applicants.
A Paragraph IV challenge would likely target one or more of the following:
| Vulnerability |
Potential challenge |
| Solid-dispersion definition |
The accused or claimed product is a physical mixture, not a solid dispersion |
| Written description |
The full breadth of polymer, dose and composition ranges is not adequately supported |
| Enablement |
The specification does not enable the full combinations across all three compounds and polymers |
| Obviousness |
Combining known CFTR modulators with known dispersion technologies was predictable |
| Crystalline Form A |
The X-ray limitation is not met or the form claim is anticipated |
| Manufacturing claims |
The accused process uses a different mixing or compression sequence |
| Method claims |
The product label does not induce treatment of the specified genotype populations |
The strongest commercial claims are likely claims 1, 3, 4 and 5. Claims 4 and 5 have greater factual specificity but also more design-around opportunities. Claim 1 has broader dosage and polymer coverage but presents greater claim-construction and validity exposure.
How strong is the patent estate for Trikafta?
The patent estate should be evaluated as a layered structure rather than as a single patent.
| Layer |
Protection target |
Relevance |
| Active-ingredient patents |
Elexacaftor, tezacaftor and ivacaftor chemistry |
May cover compounds, intermediates or therapeutic use |
| Solid-state patents |
Crystalline Form A of elexacaftor |
Blocks use of a specified polymorph |
| Combination patents |
Three-modulator therapy |
Protects the regimen and patient population |
| Formulation patents |
Separate polymeric solid dispersions |
Directly relevant to Trikafta tablets |
| Process patents |
Mixing and compression sequence |
Adds manufacturing-specific barriers |
| Regulatory exclusivity |
NDA approval and pediatric exclusivity |
Controls timing of ANDA or 505(b)(2) activity |
| Trademark and trade dress |
Trikafta commercial presentation |
Commercial, not patent, protection |
The formulation patent is more important than a conventional excipient patent because it connects the active ingredients, dispersion technology, dose ranges and single-tablet architecture. A generic applicant that copies the marketed dosage form may face multiple infringement theories.
How does US 11,179,367 compare with a generic launch scenario?
Scenario 1: Exact single-tablet copy
A tablet containing 100 mg elexacaftor, 50 mg tezacaftor and 75 mg ivacaftor, using the claimed 80% dispersions and excipient ranges, presents the highest infringement risk. Claims 4 and 5 are directly relevant, as are claims 1 and 3.
Scenario 2: Same actives, separate tablets
Separating elexacaftor, tezacaftor and ivacaftor into different dosage units may avoid claims requiring a single tablet. It may not avoid claims 1 or 3 if the composition is treated as a combined pharmaceutical composition and retains the required two solid dispersions.
Scenario 3: Different polymer system
Changing hydroxypropyl methylcellulose or hydroxypropyl methylcellulose acetate succinate may avoid claims 4 and 5. Claim 1 remains a concern because it does not require a named polymer.
Scenario 4: Non-dispersed formulation
A formulation using crystalline or amorphous active ingredient without the claimed solid-dispersion structure may avoid claims 1 through 5, assuming the product also avoids claim 6 and the crystalline-form claims.
Scenario 5: Different elexacaftor polymorph
A different solid form may avoid claims 7 through 9. It does not independently resolve the broader composition claims.
What biosimilar risks exist?
Trikafta is a small-molecule drug, not a biologic. Biosimilar litigation under the Public Health Service Act and the Purple Book is therefore not the relevant pathway.
The primary competitive routes are:
- ANDA approval under section 505(j);
- 505(b)(2) applications for materially different formulations or indications; and
- ordinary small-molecule patent litigation involving Paragraph IV certifications.
A follow-on product must address both regulatory exclusivity and the Orange Book-listed patent estate. Patent litigation risk is likely to center on formulation, polymorph, combination and method-of-use claims rather than biosimilar interchangeability.
What is the commercial exposure?
Trikafta is Vertex’s principal cystic-fibrosis product and one of the company’s largest revenue sources. Its commercial exposure includes:
- the core U.S. CF market;
- treatment expansion into younger age groups;
- label expansion for additional responsive mutations;
- conversion from older CFTR-modulator regimens; and
- international Kaftrio sales.
Because the patent claims reach the marketed combination and tablet architecture, an early generic launch could affect the entire three-drug regimen rather than a single ingredient. The precise revenue impact depends on the timing of generic entry, settlement terms, authorized-generic strategy, pediatric exclusivity and the survival of separate compound and formulation patents.
Key Takeaways
- US 11,179,367 is a Vertex-related patent directed to elexacaftor, tezacaftor and ivacaftor compositions.
- Its principal technical feature is the use of separate polymer-based solid dispersions for tezacaftor and ivacaftor.
- Claims 4 and 5 closely track commercial single-tablet formulations.
- Claims 7 through 9 add protection for Crystalline Form A of Compound I, understood to be elexacaftor.
- Claims 10 and 11 cover oral cystic-fibrosis treatment in specified genotype populations.
- Claims 12 and 13 cover selected mixing and compression processes.
- The patent has a nominal term extending to approximately April 2039, subject to the certified USPTO term and any applicable extension.
- Generic competition would proceed through ANDA or 505(b)(2) pathways, not biosimilar approval.
- The main design-around options are changing the dispersion system, polymer, dosage-unit architecture, crystalline form or manufacturing sequence.
- The patent should be analyzed with separate compound, polymorph, combination, Orange Book and regulatory-exclusivity protections.
FAQs
Does US 11,179,367 cover elexacaftor as a chemical compound?
No. The claims provided primarily cover compositions containing elexacaftor, including a specified crystalline form. They do not, on their face, claim the complete chemical structure of elexacaftor as a standalone compound.
Can a generic avoid the patent by using two tablets instead of one?
Potentially. A two-tablet product may avoid the single-tablet limitations in claims 4 and 5, but it could remain exposed to broader composition claims 1 and 3 depending on how the product is characterized.
Does changing the polymer eliminate infringement risk?
Not necessarily. Claims 4 and 5 identify specific polymer systems, but claim 1 broadly recites 10 wt% to 30% polymer without naming a particular polymer.
Is Crystalline Form A required for every claim?
No. Crystalline Form A is required by claims 7 through 9. It is not expressly required by claims 1 through 6, although the specification and prosecution history may affect construction of the broader claims.
Would a 505(b)(2) applicant face the same patent issues as an ANDA applicant?
Often yes, but the relevant certifications and litigation theories can differ. A 505(b)(2) applicant may face patent claims directed to formulation, polymorph, method of use or manufacturing even where it does not seek to copy every feature of the reference product.
References
-
United States Patent No. 11,179,367. (2021). Pharmaceutical compositions comprising CFTR modulators. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2023). TRIKAFTA (elexacaftor, tezacaftor, and ivacaftor tablets) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Vertex Pharmaceuticals Incorporated. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.
